Pharmaceutical

GLB-001 by GluBio Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

Dec 20, 2023 - 18:00
GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood o...

Next Article

GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts

STAT+: Pharmalittle: Biotech investors push to extend t...

Oct 18, 2023

STAT+: Leaked version of EFTA-India free trade deal sparks alarm over access to medicines

STAT+: Leaked version of EFTA-India free trade deal spa...

Feb 15, 2024

AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer

AstraZeneca and MSD’s Lynparza combo bags FDA approval ...

Jun 1, 2023